Zimmer Biomet Holdings Inc (ZBH) : First Manhattan Co reduced its stake in Zimmer Biomet Holdings Inc by 1.4% during the most recent quarter end. The investment management company now holds a total of 2,542,607 shares of Zimmer Biomet Holdings Inc which is valued at $317,368,206 after selling 36,151 shares in Zimmer Biomet Holdings Inc , the firm said in a disclosure report filed with the SEC on Jul 14, 2016.Zimmer Biomet Holdings Inc makes up approximately 1.90% of First Manhattan Co’s portfolio.
Other Hedge Funds, Including , Fisher Asset Management reduced its stake in ZBH by selling 9,598 shares or 5.24% in the most recent quarter. The Hedge Fund company now holds 173,552 shares of ZBH which is valued at $21,792,925. Zimmer Biomet Holdings Inc makes up approx 0.04% of Fisher Asset Management’s portfolio.Creative Planning boosted its stake in ZBH in the latest quarter, The investment management firm added 691 additional shares and now holds a total of 8,982 shares of Zimmer Biomet Holdings Inc which is valued at $1,127,870. Zimmer Biomet Holdings Inc makes up approx 0.01% of Creative Planning’s portfolio. Daiwa Sb Investments Ltd. added ZBH to its portfolio by purchasing 8,890 company shares during the most recent quarter which is valued at $1,110,272. Zimmer Biomet Holdings Inc makes up approx 0.32% of Daiwa Sb Investments Ltd.’s portfolio.
Zimmer Biomet Holdings Inc closed down -0.6 points or -0.48% at $124.82 with 11,81,455 shares getting traded on Monday. Post opening the session at $125.26, the shares hit an intraday low of $124.54 and an intraday high of $126.079 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Zimmer Biomet Holdings Inc reported $2.00 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.93. The company had revenue of $1904.00 million for the quarter, compared to analysts expectations of $1878.31 million. The company’s revenue was up 67.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.54 EPS.
Many Wall Street Analysts have commented on Zimmer Biomet Holdings Inc. Company shares were Reiterated by Needham on Jul 18, 2016 to “Buy”, Firm has raised the Price Target to $ 143 from a previous price target of $134 .Zimmer Biomet Holdings Inc was Initiated by Guggenheim to “Neutral” on Jun 9, 2016. Company shares were Reiterated by Barclays on Apr 29, 2016 to “Overweight”, Firm has raised the Price Target to $ 135 from a previous price target of $130 .
Zimmer Biomet Holdings Inc. formerly Zimmer Holdings Inc. is a musculoskeletal healthcare company. The Company designs manufactures and markets orthopedic reconstructive products; sports medicine biologics extremities and trauma products; spine bone healing craniomaxillofacial and thoracic products; dental implants and related surgical products. The Company manages its operations through three geographic segments: the Americas comprising principally of the United States and includes other North Central and South American markets; Europe comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers and directly to dental practices and dental laboratories.